These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15934897)

  • 61. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
    Fava M; Wiltse C; Walker D; Brecht S; Chen A; Perahia D
    J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.
    Goldstein DJ; Lu Y; Detke MJ; Wiltse C; Mallinckrodt C; Demitrack MA
    J Clin Psychopharmacol; 2004 Aug; 24(4):389-99. PubMed ID: 15232330
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
    Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
    J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder.
    Liu X; Tepper PG; Able SL
    Int Clin Psychopharmacol; 2011 May; 26(3):173-80. PubMed ID: 21278576
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Response to duloxetine in a depressed, treatment-resistant adolescent female.
    Delgado SV; Saldaña SN; Barzman DH; Coffey B
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):889-94. PubMed ID: 18315460
    [No Abstract]   [Full Text] [Related]  

  • 66. VEGF plasma level variations in duloxetine-treated patients with major depression.
    Fornaro M; Rocchi G; Escelsior A; Contini P; Ghio M; Colicchio S; De Berardis D; Amore M; Fornaro P; Martino M
    J Affect Disord; 2013 Nov; 151(2):590-595. PubMed ID: 23871390
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
    Wang J; Liu X; Mullins CD
    Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Duloxetine contributing to a successful multimodal treatment program for peripheral femoral neuropathy and comorbid 'reactive depression' in an adolescent.
    Kachko L; Ben Ami S; Liberman A; Birk E; Kronenberg S
    Pain Res Manag; 2011; 16(6):457-9. PubMed ID: 22184557
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of antidepressants on melatonin metabolite in depressed patients.
    Carvalho LA; Gorenstein C; Moreno R; Pariante C; Markus RP
    J Psychopharmacol; 2009 May; 23(3):315-21. PubMed ID: 18562432
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Duloxetine-induced life-threatening long QT syndrome.
    Štuhec M
    Wien Klin Wochenschr; 2013 Mar; 125(5-6):165-6. PubMed ID: 23440523
    [No Abstract]   [Full Text] [Related]  

  • 71. Duloxetine in the treatment of depression: an overview.
    Monteleone F; Caputo M; Tecce MF; Capasso A
    Cent Nerv Syst Agents Med Chem; 2011 Sep; 11(3):174-83. PubMed ID: 21919872
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Antidepressant Duloxetine Inhibits Platelet Function and Protects against Thrombosis.
    Lozano PA; Alarabi AB; Garcia SE; Boakye ET; Kingbong HT; Naddour E; Villalobos-García D; Badejo P; El-Halawany MS; Khasawneh FT; Alshbool FZ
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269729
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Duloxetine, an antidepressant with analgesic properties - a preliminary analysis.
    Onuţu AH
    Rom J Anaesth Intensive Care; 2015 Oct; 22(2):123-128. PubMed ID: 28913467
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Some antipsychotics' effect on suicide; duloxetine's promise for elderly.
    Behav Healthc Tomorrow; 2004 Dec; 13(6):10-1. PubMed ID: 15700610
    [No Abstract]   [Full Text] [Related]  

  • 75. Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East.
    Hong J; Novick D; Moneta MV; El-Shafei A; Dueñas H; Haro JM
    Clin Pract Epidemiol Ment Health; 2017; 13():145-155. PubMed ID: 29238391
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Local control for identifying subgroups of interest in observational research: persistence of treatment for major depressive disorder.
    Faries DE; Chen Y; Lipkovich I; Zagar A; Liu X; Obenchain RL
    Int J Methods Psychiatr Res; 2013 Sep; 22(3):185-94. PubMed ID: 23956114
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antidepressant Use in Chronic Pain Management: Is There Evidence of a Role for Duloxetine?
    Leo RJ; Barkin RL
    Prim Care Companion J Clin Psychiatry; 2003 Jun; 5(3):118-123. PubMed ID: 15154022
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder.
    Haider M; Shafqat MN
    Neuropsychiatr Dis Treat; 2017; 13():2505-2508. PubMed ID: 29042779
    [No Abstract]   [Full Text] [Related]  

  • 79. Comment on: "cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective".
    Liedgens H; Henske R
    Appl Health Econ Health Policy; 2013 Oct; 11(5):553-4. PubMed ID: 23918680
    [No Abstract]   [Full Text] [Related]  

  • 80. Introduction to the Special Issue of PharmacoEconomics on Major Depressive Disorders.
    Greenberg PE; Sisitsky T
    Pharmacoeconomics; 2021 Jun; 39(6):617. PubMed ID: 33982197
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.